Fractyl’s Rejuva platform demonstrates potent and durable effects of a single dose of a human GLP-1 pancreatic gene therapy transgene vs semaglutide for diabetes and obesity
GLP-1-based pancreatic gene therapy maintained weight loss after semaglutide withdrawal in rodents
Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DM
Fractyl initiates Global Registry Study of the Revita System
Fractyl’s Revita DMR System commercially available in Germany
Fractyl initiates Erase T2DM task force to establish root cause mechanisms underlying T2DM
Fractyl Health reports latest Revita DMR outcomes for T2DM
Two-year Revita DMR outcomes show durability of procedure in diabetics
Fractyl’s pioneering Metabolic Balance Model identifies new model of intestine’s role in metabolism
Fractyl gains US$100 million financing to expand clinical development programs for T2DM
